BioNexus Gene Lab (BGLC) director discloses 1,261 common shares in Form 3
Rhea-AI Filing Summary
BioNexus Gene Lab Corp reports initial insider holdings for director Low Jook Yuen. The filing shows beneficial ownership of 1,261 shares of common stock, held directly. This Form 3 establishes the director’s reported equity position as an insider of the company.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Low Jook Yuen
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | COMMON STOCK | -- | -- | -- |
Holdings After Transaction:
COMMON STOCK — 1,261 shares (Direct)
Key Figures
Common stock holdings: 1,261 shares
Holding entries: 1
Net buy/sell shares: 0
3 metrics
Common stock holdings
1,261 shares
Total shares of common stock held directly by the director following the reported holding entry
Holding entries
1
Number of holding entries reported for common stock in the Form 3
Net buy/sell shares
0
No net buy or sell activity; only a holding position is reported
Key Terms
COMMON STOCK, Unknown transaction code, direct_or_indirect
3 terms
COMMON STOCK financial
"security_title field lists COMMON STOCK as the equity security"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Unknown transaction code regulatory
"transaction_code_description notes an Unknown transaction code for this holding"
direct_or_indirect financial
"The direct_or_indirect field is D, indicating direct ownership of the shares"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does BioNexus Gene Lab Corp (BGLC) disclose in this Form 3?
BioNexus Gene Lab Corp discloses that director Low Jook Yuen holds 1,261 shares of common stock directly. This Form 3 serves as the initial insider ownership report for this director at the company.
Is the ownership reported by the BGLC director direct or indirect?
The Form 3 shows the ownership type as direct, coded as “D” in the filing. This means the 1,261 common shares are held directly by the reporting person rather than through an intermediary entity.
Does the BioNexus Gene Lab (BGLC) Form 3 show any insider buying or selling?
The Form 3 does not report any buy or sell transactions; it only lists a holding entry. It records that the director’s position consists of 1,261 directly held common shares, with no accompanying acquisition or disposition activity.
Who is the reporting person in BioNexus Gene Lab Corp (BGLC)’s Form 3?
The reporting person is Low Jook Yuen, identified in the filing as a director of BioNexus Gene Lab Corp. The Form 3 sets out this director’s initial reported ownership of 1,261 common shares held directly.